These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 31520636)

  • 1. A Rare Combination of CYP2C9*3/*3 and VKORC1 1639AA in a Patient Who Had Myxoma and Thromboembolism.
    Son KH; Lee SI; Choi CH; Park KY; Park CH
    Ann Thorac Surg; 2020 Apr; 109(4):e283-e284. PubMed ID: 31520636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
    Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
    Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China.
    Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
    Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
    Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
    Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
    Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
    [No Abstract]   [Full Text] [Related]  

  • 19. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.